Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Olga Alvarez

Licensed Practical Nurse Hialeah, FL Nurse Practitioner

NPI 1932568516 CMS profile 11226187

19500 Bobolink Dr, Hialeah, FL 33015

Open in the dashboard

General payments

$248

2 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Olga Alvarez of Hialeah, FL is reported in the CMS Open Payments database as having received $248 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Licensed Practical Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 1
2021 General $123 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olga Alvarez
  • Licensed Practical Nurse median
  • Middle half of Licensed Practical Nurse
  • National median

In program year 2025, general payments to Olga Alvarez were reported at $0. Among 149 Licensed Practical Nurse profiles paid that year, the median was $39 and the middle half received between $23 and $109.

Show as a table
Year Olga Alvarez Licensed Practical Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $123 $29 $19–$120 $132
2022 $0 $35 $19–$122 $149
2023 $125 $51 $18–$125 $160
2024 $0 $53 $23–$139 $164
2025 $0 $39 $23–$109 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Stryker Corporation $125 1 payment
  2. Medical Device Business Services, Inc. $123 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $248 2 payments
Products named General payments · program years 2021–2023
  1. MAKO $125 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 197 drugs

Part D claims

20,890

Prescriptions dispensed, refills included

Drug cost

$369,470

Paid at the pharmacy, in all

Branded share of claims

18.4%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 162 $63,953
Eliquis Apixaban Brand 75 $34,817
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 385 $26,369
Aripiprazole Generic 89 $17,410
Pradaxa Dabigatran Etexilate Mesylate Brand 88 $16,664
Insulin Aspart Flexpen Insulin Aspart Brand 67 $9,192
Mirtazapine Generic 385 $8,851
Lumigan Bimatoprost Brand 32 $7,703
Entresto Sacubitril/Valsartan Brand 13 $7,669
Colesevelam Hcl Generic 15 $6,913

The 10 drugs with the highest cost, of 197 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Licensed Practical Nurse in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record